Asset profile
dapirolizumab pegol · United Community (UCB)
- Indication
- systemic lupus erythematosus
- Also known as
- DZP, dapirolizumab pegol
Company
UCBUnited Community
UCBUnited CommunityUnited Community Banks Inc provides a wide range of financial products and services to the commercial, retail, governmental, educational, energy, health care and real estate sectors. This includes a variety of deposit products, secured and unsecured loans, mor…
On the calendar
Timeline
Newest first.
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT04976322 | Phase 3 | Enrolling by invitation | Aug 7, 2030 | 760 | 34 of 123 sites in the United States |
| NCT06617325 | Phase 3 | Recruiting | May 31, 2028 | 450 | 63 of 242 sites in the United States |
| NCT02804763 | Phase 2 | Completed | May 31, 2018 | 182 | 25 of 71 sites in the United States |
| NCT04294667 | Phase 3 | Completed | May 22, 2024 | 321 | 60 of 177 sites in the United States |
More from United Community
Other drugs and candidates from the same company tracked in this sector.